/Becton%20Dickinson%20%26%20Co_%20logo%20on%20phone-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $54.8 billion, Becton, Dickinson and Company (BDX) is a global medical technology firm that develops, manufactures, and sells medical devices, laboratory equipment, and diagnostic products. BD serves healthcare institutions, researchers, laboratories, and patients worldwide.
Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and BDX fits this criterion perfectly. Its operations are organized into three principal segments: BD Medical, BD Life Sciences, and BD Interventional, covering areas from medication delivery and diagnostics to surgical and interventional solutions.
Shares of the Franklin Lakes, New Jersey-based company have fallen 24.1% from its 52-week high of $251.99. Becton, Dickinson and Company’s shares have increased 11.9% over the past three months, outperforming the broader S&P 500 Index’s ($SPX) 8.9% gain over the same time frame.
In the longer term, BDX stock is down 15.7% on a YTD basis, lagging behind SPX’s 10.6% rise. Moreover, shares of the medical device manufacturer have dropped 19.1% over the past 52 weeks, compared to the 17.8% return of the SPX over the same time frame.
BDX stock has been trading below its 50-day and 200-day moving averages since early February. However, the stock has moved above its 50-day moving average since July.
Shares of Becton Dickinson climbed 8.9% on Aug. 7 after the company reported stronger-than-expected Q3 2025 results, with adjusted EPS of $3.68 and revenue of $5.5 billion. Growth was driven by a 14.4% increase in sales from its medical unit to $2.93 billion, slightly topping forecasts, as demand for drug-delivery devices remained strong. Additionally, BD raised its 2025 adjusted profit forecast to a range of $14.30 per share - $14.45 per share.
Nevertheless, rival ResMed Inc. (RMD) has outpaced BDX stock. RMD stock has gained 19.7% on a YTD basis and 11.9% over the past 52 weeks.
Despite the stock’s underperformance over the past year, analysts remain moderately optimistic on BDX. The stock has a consensus rating of “Moderate Buy” from the 17 analysts in coverage, and the mean price target of $214.31 is a premium of 12.1% to current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
